A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Arvinas, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 227,600 shares of ARVN stock, worth $4.26 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
227,600
Previous 41,700 445.8%
Holding current value
$4.26 Million
Previous $1.11 Million 404.95%
% of portfolio
0.01%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$23.66 - $32.73 $4.4 Million - $6.08 Million
185,900 Added 445.8%
227,600 $5.61 Million
Q2 2024

Aug 14, 2024

SELL
$24.46 - $40.4 $139,422 - $230,280
-5,700 Reduced 12.03%
41,700 $1.11 Million
Q1 2024

May 15, 2024

BUY
$36.38 - $52.31 $1.72 Million - $2.48 Million
47,400 New
47,400 $1.96 Million
Q3 2023

Nov 14, 2023

SELL
$19.64 - $28.21 $1.07 Million - $1.54 Million
-54,600 Reduced 73.19%
20,000 $392,000
Q2 2023

Aug 14, 2023

BUY
$21.73 - $31.43 $1.16 Million - $1.68 Million
53,600 Added 255.24%
74,600 $1.85 Million
Q1 2023

May 15, 2023

BUY
$26.15 - $37.26 $549,150 - $782,460
21,000 New
21,000 $573,000
Q2 2022

Aug 15, 2022

BUY
$36.01 - $74.24 $176,449 - $363,776
4,900 New
4,900 $206,000
Q1 2022

May 16, 2022

SELL
$60.27 - $81.57 $13.1 Million - $17.7 Million
-216,900 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$65.85 - $96.21 $7.85 Million - $11.5 Million
-119,200 Reduced 35.47%
216,900 $17.8 Million
Q3 2021

Nov 15, 2021

BUY
$73.2 - $107.87 $1.71 Million - $2.52 Million
23,394 Added 7.48%
336,100 $27.6 Million
Q2 2021

Aug 16, 2021

BUY
$60.45 - $84.26 $1.44 Million - $2.01 Million
23,806 Added 8.24%
312,706 $24.1 Million
Q1 2021

May 17, 2021

BUY
$58.19 - $91.37 $215,303 - $338,069
3,700 Added 1.3%
288,900 $19.1 Million
Q4 2020

Feb 16, 2021

SELL
$20.19 - $84.93 $2.43 Million - $10.2 Million
-120,500 Reduced 29.7%
285,200 $24.2 Million
Q3 2020

Nov 16, 2020

BUY
$22.99 - $36.34 $1.23 Million - $1.94 Million
53,400 Added 15.16%
405,700 $9.58 Million
Q2 2020

Aug 14, 2020

BUY
$29.88 - $56.74 $7.41 Million - $14.1 Million
247,900 Added 237.45%
352,300 $11.8 Million
Q1 2020

May 15, 2020

BUY
$33.0 - $54.5 $2.51 Million - $4.14 Million
76,000 Added 267.61%
104,400 $4.21 Million
Q4 2019

Feb 14, 2020

BUY
$15.39 - $44.38 $437,076 - $1.26 Million
28,400 New
28,400 $1.17 Million

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $997M
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.